Expression of apoptosis-related markers in malignant epithelial tumours of the lacrimal gland and their relation to clinical outcome

Strianese, Diego; Baldi, Gianluca; Staibano, Stefania; Baldi, Alfonso; Rosa, Gaetano De; Tranfa, Fausto; Bonavolontà, Giulio

doi:10.1136/bjo.2007.118661

Cited by 17 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When mutated, p53 fails in leading all the damaged cells to apoptosis and some progress then further to full-blown cancer. A similar correlation between the levels of p53 and TUNEL was recently reported by strianese et al 16 who examined lachrymal gland malignancies. The fact that we found no significant correlation between the expression rates of Skp2 and heparanase, despite the fact that both were associated with poor survival, may be explained by their being involved in unrelated lethal pathways.…”

Section: Methodssupporting

confidence: 56%

Skp2 and salivary cancer

Ben‐Izhak

Akrish²,

Gan³

et al. 2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

Salivary malignancies are rare, heterogeneous, unpredictable in clinical behavior and seldom studied. Skp2 expression was examined in salivary malignancies (n = 75) for a prolonged period (20 years). In 40/75 (53%) cases Skp2 expression rate (staining level) was ≤4% while in the remainder (47%) it was >4%. Correlation between enhanced Skp2 and enhanced p53 staining levels was significant (p = 0.042), as were correlation rates between enhanced Skp2 and reduced p27 staining levels (p = 0.01) and enhanced Skp2 and enhanced TUNEL staining levels (p = 0.008). Survival probability rates dropped when Skp2 expression increased. Median patient survival for reduced-stained-tumor patients (≤4%) was 143 months and significantly lower, 49 months (p = 0.016), for enhanced-stained-tumor patients (>4%). Survival probability at five years was 82% for the former group (≤4%) and 47% for the latter (>4%). At 20 years, survival dropped to 35% and 18% respectively (p = 0.016). More extensive and aggressive therapy did not reduce mortality in patients with enhanced Skp2-expressing tumors. Significant correlations between poor survival and significantly altered expression rates of Skp2, p27, p53, TUNEL and heparanase in salivary malignancies, suggest a biological role in salivary cancer pathogenesis for these five markers. The findings may be used for prognostic and follow-up purposes.

show abstract

Section: Methodssupporting

confidence: 56%

Skp2 and salivary cancer

Ben‐Izhak

Akrish²,

Gan³

et al. 2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…In contrast with these findings, Friedrich and Bleckmann showed that only the stage of the tumor had an impact on prognosis whereas the localization or the histological subtypes did not show any impact on survival [17]. Strianese et al [18 ] studied the relationship among apoptosis related markers and prognosis in 21 malignant epithelial tumors of the lacrimal gland, including 11 adenoid cystic carcinomas. They found that increased Bcl-2 staining was significantly correlated with a poor survival.…”

Section: Malignant Lacrimal Gland Tumorsmentioning

confidence: 92%

Epithelial tumors of the lacrimal gland: an update

Bernardini¹,

Devoto²,

Croxatto³

2008

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Differential expression of apoptotic molecules has also been seen between highly metastatic ACC cell lines compared with their less metastatic counterparts 48. The specific role of B-cell leukaemia/lymphoma 2 (BCL-2) is less clear as upregulation of BCL-2 was found to correlate with poor outcome in one study63 but not in another 64…”

Section: Metastatic Acc Of the Lacrimal Glandmentioning

confidence: 99%

Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland

Tourneau

Razak

Lévy

et al. 2010

British Journal of Ophthalmology

View full text Add to dashboard Cite

Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.

show abstract

Expression of apoptosis-related markers in malignant epithelial tumours of the lacrimal gland and their relation to clinical outcome

Cited by 17 publications

References 25 publications

Skp2 and salivary cancer

Skp2 and salivary cancer

Epithelial tumors of the lacrimal gland: an update

Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland

Contact Info

Product

Resources

About